Form 4: CytomX CFO Ogden Receives Significant Equity Grants

CytomX Therapeutics' CFO Christopher Ogden was granted 90,000 restricted stock units and 325,000 stock options, aligning his interests with shareholders.

Summary

• Christopher Ogden, Chief Financial Officer of CytomX Therapeutics, Inc. (CTMX), was granted 90,000 Restricted Stock Units (RSUs) and 325,000 stock options on February 2, 2026.
• The RSUs entitle Mr. Ogden to receive one share of Common Stock for each RSU upon vesting, with 1/3rd vesting annually on March 15, starting March 15, 2027.
• The stock options have an exercise price of $6.09 per share and an expiration date of February 1, 2036.
• The stock options vest monthly at a rate of 1/48th from February 2, 2026, becoming fully vested on the fourth anniversary of the vesting commencement date.
• Following these transactions, Mr. Ogden beneficially owns 316,271 shares of Common Stock (including 239,987 RSUs) and 325,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive alignment with shareholder interests through equity compensation, a standard practice for retention and motivation.

Positives

• The grant of 90,000 Restricted Stock Units (RSUs) and 325,000 stock options to the Chief Financial Officer demonstrates continued commitment to the company and aligns management's interests with long-term shareholder value.
• Equity compensation is a standard practice for retaining key executives and incentivizing performance, suggesting stability in leadership.

Future Outlook

The grants include specific vesting schedules for both RSUs and stock options, extending through March 15, 2029, for RSUs and February 2, 2030, for stock options (assuming a four-year vesting period), contingent on the CFO's continued service. This indicates a long-term incentive structure for key management.

Industry Context

StockSavvy.ai notes that equity grants to executive officers, such as this Form 4 filing for CytomX Therapeutics' CFO, are a common practice in the biotechnology and pharmaceutical industries. These grants serve to attract, retain, and motivate key talent, aligning their financial incentives with the long-term success and stock performance of the company. This is particularly relevant in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a standard component of executive remuneration packages across the biotech industry, comparable to practices at companies like Amgen or Gilead Sciences.
• The vesting schedules (annual for RSUs, monthly over four years for options) are typical for executive incentive plans, designed to encourage long-term commitment and performance, similar to those observed in other publicly traded biopharmaceutical firms.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making. However, future share issuance upon vesting and exercise will result in minor dilution.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation.

Next Steps

• Vesting of 1/3rd of the RSUs annually on March 15, starting March 15, 2027.
• Monthly vesting of 1/48th of the stock options from February 2, 2026, until fully vested on the fourth anniversary.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive and does not contain information that would fundamentally alter the investment thesis for CytomX Therapeutics. While it signals executive alignment, it is not a catalyst for a strong buy or sell recommendation on its own. Investors should continue to hold and monitor broader company performance and strategic developments.

Keywords

CytomX Therapeutics, CTMX, Christopher Ogden, Chief Financial Officer, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Vesting Schedule